Daan van Valkengoed
- Name
- D.W. van Valkengoed MSc
- ORCID iD
- 0009-0006-7830-2553
- Valkengoed D.W. van, Rottschäfer V. & Lange E.C.M. de (2026), Simulation-based assessment of the P-glycoprotein expression-activity relationship shows a drug and system dependency, Journal of Pharmacokinetics and Pharmacodynamics 53: 10.
- Mouraux A., Gousset S., Alvarez B., Baiula M., Bakker W., Bedini A., Bertayli M., Budda D., Carr R., Cuna E., Díaz Ó., Donner N., Giraldo J., Groeneveld G., Gülave B., Guydan D., Hijma H., Maldonado R., Renault P., Rinaudo C., Elaissaiss‐Schaap J., Spiros A., Stoeber S., Takkala P., Valkengoed D.W. van, Hasselt C. van & Lange E.C.M. de (2026), In silico prediction of novel effective combinational treatment of chronic pain in individual patients: a joint white paper of the H2020 QSPainRelief consortium, British Journal of Pharmacology : .
- Valkengoed D.W. van, Hirasawa M., Rottschäfer V. & Lange E.C.M. de (2025), Reliability of in vitro data for the mechanistic prediction of brain extracellular fluid pharmacokinetics of P-glycoprotein substrates in vivo; are we scaling correctly?, Journal of Pharmacokinetics and Pharmacodynamics 52: 16.
- Gaag S. van der, Jordens T., Yaqub M., Grijseels R., Valkengoed D.W. van, Langen E.N. de, Broek R. van den, Thijssen V.L.J.L., Langen A.J. de, Kouwenhoven M.C.M., Bahce I., Westerman B.A., Hendrikse N.H. & Bartelink I.H. (2025), Physiologically based pharmacokinetic model of tyrosine kinase inhibitors to predict target site penetration, with PET-guided verification, CPT: Pharmacometrics & Systems Pharmacology 14(5): 918-928.
- Valkengoed D.W. van, Krekels E.H.J. & Knibbe C.A.J. (2024), All you need to know about allometric scaling: an integrative review on the theoretical basis, empirical evidence, and application in human pharmacology, Clinical Pharmacokinetics 64(2): 173-192.